Junichi Asaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junichi Asaka has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Kenzo Kudo
Department of pharmacy, Iwate Medical University Hospital, 19-1Uchimaru, Morioka, Iwate 020-8505 Japan ; Department of Clinical Pharmaceutics, School of Pharmacy, Iwate Medical University, 2-1-1 Nishitokuta, Yahaba, Iwate 028-3694 Japan
2 shared publications - Haruki Ujiie
Department of Pharmacy, Iwate Medical University Hospital, Iwate, Japan
1 shared publication - Hiroaki Takahashi
Division of Clinical Pharmaceutics and Pharmacy Practice, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University, Iwate, Japan
1 shared publication - Kanon Sugawara
Department of Pharmacy, Iwate Medical University Hospital, Iwate, Japan
1 shared publication - Masaki Sato
Department of Pharmacy, Iwate Medical University Hospital, Iwate, Japan
1 shared publication - Satoru Nihei
Department of Pharmacy, Iwate Medical University Hospital, Iwate, Japan
1 shared publication
Latest Publications
- 28 November 2023
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 93 (4) , 319-328
Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study
Purpose Acneiform rash is frequently observed in patients undergoing cancer treatment with anti-epidermal growth factor receptor (EGFR) antibody drugs and can often necessitate treatment discontinuation. However, the specific changes in skin parameters resulting from anti-EGFR antibody drug administration are poorly understood. Therefore, this study aimed to longitudinally and quantitatively evaluate the changes in skin parameters (transepidermal water loss [TEWL], hydration level, and sebum level) caused by anti-EGFR antibody drugs and investigate their potential as control markers for skin disorders. Methods This prospective study included 12 patients with colorectal cancer who received anti-EGFR antibody drugs for the first time. The assessment items included the grade of acneiform rash and skin parameters (TEWL, hydration level, and sebum level), which were observed for up to 6 weeks after administration of the medication. Results The enrolled patients were classified into two groups based on the grade of acneiform rash caused by anti-EGFR antibody drugs: “Grade 1 and lower,” and “Grade 2 and higher.” The skin parameters were compared between these groups. The results showed that in the “Grade 2 and higher” group, TEWL in the face (at week 2 of administration), chest (baseline, weeks 2 and 6 of administration), and back (at week 2 of administration) were significantly higher than those in the “Grade 1 and lower” group. However, the two groups showed no significant differences in hydration or sebum levels at any time point. Conclusion TEWL can serve as a marker for acneiform rashes induced by anti-EGFR antibody drugs during cancer treatment.
- 28 November 2023
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 93 (4) , 319-328
Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study
Purpose Acneiform rash is frequently observed in patients undergoing cancer treatment with anti-epidermal growth factor receptor (EGFR) antibody drugs and can often necessitate treatment discontinuation. However, the specific changes in skin parameters resulting from anti-EGFR antibody drug administration are poorly understood. Therefore, this study aimed to longitudinally and quantitatively evaluate the changes in skin parameters (transepidermal water loss [TEWL], hydration level, and sebum level) caused by anti-EGFR antibody drugs and investigate their potential as control markers for skin disorders. Methods This prospective study included 12 patients with colorectal cancer who received anti-EGFR antibody drugs for the first time. The assessment items included the grade of acneiform rash and skin parameters (TEWL, hydration level, and sebum level), which were observed for up to 6 weeks after administration of the medication. Results The enrolled patients were classified into two groups based on the grade of acneiform rash caused by anti-EGFR antibody drugs: “Grade 1 and lower,” and “Grade 2 and higher.” The skin parameters were compared between these groups. The results showed that in the “Grade 2 and higher” group, TEWL in the face (at week 2 of administration), chest (baseline, weeks 2 and 6 of administration), and back (at week 2 of administration) were significantly higher than those in the “Grade 1 and lower” group. However, the two groups showed no significant differences in hydration or sebum levels at any time point. Conclusion TEWL can serve as a marker for acneiform rashes induced by anti-EGFR antibody drugs during cancer treatment.
- 13 March 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (4) , 1-7
Identifying risk factors for opioid-induced neurotoxicity in cancer patients receiving oxycodone
Purpose The aim of this study was to determine the frequency of opioid-induced neurotoxicity (OIN) in cancer patients receiving oral controlled-release oxycodone and to define risk factors for OIN. Methods This was a single-center, retrospective study of hospitalized adult cancer patients receiving oral controlled-release oxycodone between April 1, 2013, and April, 30, 2020. The onset of OIN within 30 days after oxycodone initiation in the study patients was investigated. OIN was defined as any of the following: delirium, hallucinations (visual or auditory), seizure, myoclonus, hyperesthesia, and excessive somnolence. Multivariate logistic regression analysis was performed to identify risk factors for OIN in patients receiving oxycodone. Results In total, 520 patients were included in this study. The number of patients with OIN was 65 (12.5%). The median time until onset of OIN after oxycodone initiation was 7.5 days. Multivariate logistic regression analysis revealed that age ≥ 65 years (OR = 2.74, 95% CI [1.30–5.78], p = 0.008), total bilirubin ≥ 1.3 mg/dL (OR = 4.85, 95% CI [2.13–11.0], p < 0.001), and concomitant use of pregabalin or mirogabalin (OR = 3.11, 95% CI [1.47–6.61], p = 0.003) were significant independent risk factors for OIN. Conclusion Age ≥ 65 years, liver dysfunction, and concomitant use of pregabalin or mirogabalin were independent risk factors for OIN in patients receiving oxycodone. Patients with these risk factors who are receiving oxycodone should be monitored for OIN, especially early in the administration of oxycodone.
- 13 March 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (4) , 1-7
Identifying risk factors for opioid-induced neurotoxicity in cancer patients receiving oxycodone
Purpose The aim of this study was to determine the frequency of opioid-induced neurotoxicity (OIN) in cancer patients receiving oral controlled-release oxycodone and to define risk factors for OIN. Methods This was a single-center, retrospective study of hospitalized adult cancer patients receiving oral controlled-release oxycodone between April 1, 2013, and April, 30, 2020. The onset of OIN within 30 days after oxycodone initiation in the study patients was investigated. OIN was defined as any of the following: delirium, hallucinations (visual or auditory), seizure, myoclonus, hyperesthesia, and excessive somnolence. Multivariate logistic regression analysis was performed to identify risk factors for OIN in patients receiving oxycodone. Results In total, 520 patients were included in this study. The number of patients with OIN was 65 (12.5%). The median time until onset of OIN after oxycodone initiation was 7.5 days. Multivariate logistic regression analysis revealed that age ≥ 65 years (OR = 2.74, 95% CI [1.30–5.78], p = 0.008), total bilirubin ≥ 1.3 mg/dL (OR = 4.85, 95% CI [2.13–11.0], p < 0.001), and concomitant use of pregabalin or mirogabalin (OR = 3.11, 95% CI [1.47–6.61], p = 0.003) were significant independent risk factors for OIN. Conclusion Age ≥ 65 years, liver dysfunction, and concomitant use of pregabalin or mirogabalin were independent risk factors for OIN in patients receiving oxycodone. Patients with these risk factors who are receiving oxycodone should be monitored for OIN, especially early in the administration of oxycodone.